• Publications
  • Influence
Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
Androgen receptor inhibition induces a “BRCAness” state that may be exploited with PARP inhibitors in patients with advanced prostate cancer. Engineering BRCAness and chemotherapeutic sensitivityExpand
  • 66
  • 5
Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer
Purpose: We investigated MYCN-regulated molecular pathways in castration-resistant prostate cancer (CRPC) classified by morphologic criteria as adenocarcinoma or neuroendocrine to extend theExpand
  • 32
  • 1
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Maintenance of genomic stability is a critical determinant of cell survival and is necessary for growth and progression of malignant cells. Interstrand crosslinking (ICL) agents, includingExpand
  • 26
  • 1
Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer
Caveolin-1 (Cav-1) is overexpressed in aggressive and metastatic prostate cancer (PCa) and induces PCa cell proliferation. Androgens mediate lipid synthesis through acetyl-CoA carboxylase-1 (ACC1)Expand
  • 10
  • 1
  • Open Access
Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned
The adverse effects of overdiagnosis and overtreatment observed in men with clinically insignificant prostate cancers after the introduction of prostate-specific antigen-based screening are now beingExpand
  • 10
  • 1
Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration‐resistant prostate cancer models
Previous studies have shown that increased levels of chemokine receptor CXCR7 are associated with the increased invasiveness of prostate cancer cells. We now show that CXCR7 expression is upregulatedExpand
  • 14
The implications of ageing and life expectancy in prostate cancer treatment
In patients diagnosed with prostate cancer, the selection of treatment, including the type of therapy and its aggressiveness, is often based on a patient's age and life expectancy. Life expectancyExpand
  • 5
β-catenin nuclear translocation induced by HIF-1α overexpression leads to the radioresistance of prostate cancer
  • Y. Luo, M. Li, +8 authors L. Lan
  • Medicine, Biology
  • International journal of oncology
  • 12 April 2018
Hypoxia-inducible factor-1α (HIF-1α) is known to play crucial roles in tumor radioresistance; however, the molecular mechanisms responsible for the promotion of tumor radioresistance by HIF-1α remainExpand
  • 4
  • Open Access
Baseline and longitudinal plasma caveolin‐1 level as a biomarker in active surveillance for early‐stage prostate cancer
To evaluate the role of caveolin‐1 (Cav‐1) as a predictor of disease reclassification (DR) in men with early prostate cancer undergoing active surveillance (AS).
  • 7
Active surveillance in prostate cancer: new efforts, new voices, new hope
1 Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P. Almost complete uptake of active surveillance for very low-risk prostate cancer in Sweden. JAMA Oncol 2016; [Epub ahead of print].Expand
  • 2